Insights Into MetLife (MET) Q3: Wall Street Projections for Key Metrics

31.10.25 14:15 Uhr

Werte in diesem Artikel
Aktien

69,05 EUR 0,79 EUR 1,16%

Indizes

PKT PKT

17.878,0 PKT -2,0 PKT -0,01%

3.450,8 PKT 11,3 PKT 0,33%

6.840,2 PKT 17,9 PKT 0,26%

Wall Street analysts expect MetLife (MET) to post quarterly earnings of $2.33 per share in its upcoming report, which indicates a year-over-year increase of 20.7%. Revenues are expected to be $18.84 billion, up 7% from the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.8% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.Bearing this in mind, let's now explore the average estimates of specific MetLife metrics that are commonly monitored and projected by Wall Street analysts.The consensus estimate for 'Revenue- Premiums' stands at $11.41 billion. The estimate suggests a change of +7.2% year over year.The average prediction of analysts places 'Revenue- Other Revenues' at $653.32 million. The estimate indicates a change of +0.8% from the prior-year quarter.Based on the collective assessment of analysts, 'Revenue- Universal life and investment-type product policy fees' should arrive at $1.31 billion. The estimate indicates a year-over-year change of +6.5%.The consensus among analysts is that 'Revenue- Net investment income' will reach $5.47 billion. The estimate indicates a year-over-year change of +4.7%.It is projected by analysts that the 'Total Adjusted Revenue- Latin America' will reach $2.09 billion. The estimate indicates a year-over-year change of +8.4%.Analysts' assessment points toward 'Adjusted Revenue- Corporate & other- Net investment income' reaching $83.06 million. The estimate points to a change of -13.5% from the year-ago quarter.Analysts forecast 'Total Adjusted Revenue- EMEA' to reach $773.03 million. The estimate points to a change of +8.9% from the year-ago quarter.The combined assessment of analysts suggests that 'Total Adjusted Revenue- Asia' will likely reach $3.08 billion. The estimate suggests a change of +8.5% year over year.Analysts expect 'Adjusted Revenue- Asia- Net investment income' to come in at $1.31 billion. The estimate indicates a change of +15.5% from the prior-year quarter.According to the collective judgment of analysts, 'Adjusted Revenue- EMEA- Net investment income' should come in at $62.02 million. The estimate indicates a year-over-year change of +12.8%.Analysts predict that the 'Adjusted Revenue- Latin America- Net investment income' will reach $442.90 million. The estimate points to a change of +1.8% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Adjusted Revenue- Asia- Other Revenues' of $20.48 million. The estimate suggests a change of +13.8% year over year. View all Key Company Metrics for MetLife here>>> Shares of MetLife have demonstrated returns of -2.7% over the past month compared to the Zacks S&P 500 composite's +2.1% change. With a Zacks Rank #3 (Hold), MET is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MetLife, Inc. (MET): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: MetLife und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf MetLife

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf MetLife

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu MetLife Inc.

Wer­bung

Analysen zu MetLife Inc.

DatumRatingAnalyst
02.01.2018MetLife HoldDeutsche Bank AG
03.11.2017MetLife OutperformRBC Capital Markets
25.05.2017MetLife OutperformFBR & Co.
09.12.2016MetLife HoldStandpoint Research
28.11.2016MetLife Mkt PerformFBR & Co.
DatumRatingAnalyst
03.11.2017MetLife OutperformRBC Capital Markets
25.05.2017MetLife OutperformFBR & Co.
05.05.2016MetLife OutperformRBC Capital Markets
31.07.2015MetLife BuyDeutsche Bank AG
22.06.2015MetLife OutperformRBC Capital Markets
DatumRatingAnalyst
02.01.2018MetLife HoldDeutsche Bank AG
09.12.2016MetLife HoldStandpoint Research
28.11.2016MetLife Mkt PerformFBR & Co.
13.07.2016MetLife HoldDeutsche Bank AG
15.03.2016MetLife NeutralUBS AG
DatumRatingAnalyst
04.12.2006Update MetLife Inc.: UnderperformFriedman, Billings Ramsey & Co
14.09.2005MetLife DowngradeDeutsche Securities
14.09.2005Update MetLife Inc.: SellDeutsche Securities

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für MetLife Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen